← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Cyclerion Therapeutics, Inc.: Revenue grew 3.7% to $2.074M from $2M. Net loss widened to $3.528M from $3.057M. Free cash flow outflow narrowed to $3.314M from $4.333M. Operating margin contracted 5838 bps to -239.78%. Cyclerion Therapeutics, Inc.'s annual comparison also shows the balance-sheet screen falls in the distress range and requires business-model context; the earnings-quality screen is grey.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 3.7% to $2.074M from $2MOK
- Profitability — Net loss widened to $3.528M from $3.057MWatch
- Cash flow — Free cash flow outflow narrowed to $3.314M from $4.333MOK
- Margins — Operating margin contracted 5838 bps to -239.78%Watch
- Accounting — Going-concern warningWatch
- Insiders — 0 purchases and 0 salesNote
Business
These agreements also typically provide that all inventions resulting from work performed for us or relating to our business and conceived or completed during the period of employment or assignment, as applicable, shall be our exclusive property.
Where the revenue comes from
Fiscal 2025, as Cyclerion Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- License Agreement$1.0M
- Purchase Agreement$800K
- Option Agreement$274K
Leadership changes
From Cyclerion Therapeutics, Inc.'s own filings, the day they're filed.
- Peter Hecht · Chief Executive Officer · departureeff. 2023-12-01
- Ole Isacson · director · departureeff. 2023-11-19
- Anjeza Gjino · Chief Financial Officer · departureeff. 2023-10-17
Latest filings
- 8-K · Company announcement2026-08-27
- 8-K · Company announcement2026-08-25
- 10-Q · Quarterly report2026-08-04
- 10-Q · Quarterly report2026-05-12
- 8-K · Company announcement2026-04-01
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Cyclerion Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.